Insperity: $45.6 Billion Flows Through, a $10 Million Loss Stays Behind

There is an investor trap that springs shut whenever a company handles other people's money: the treasurer trap. It works like this. The treasurer of your local sports club has fifty thousand dollars in the account and a thick folder of receipts. That does not make him rich — the money belongs to the club, and the folder says to the cent who is owed what. Insperity, Inc. (NYSE: NSP) is the same thing at scale, except the numbers are impressive enough that the receipts are easy to skip. In one line: of the $45,565 million in gross billings for 2025, $6,812 million remained as revenue, of which $900 million was gross profit — and below that sat an operating loss of $10 million. So let us make a deal: before we talk about the stock, we read together what the company itself filed with the U.S. securities regulator, the SEC — the annual report (Form 10-K) for 2025 filed February 11, 2026, and the quarterly report (Form 10-Q) for March 31, 2026, filed May 1, 2026. An SEC filing is honest under penalty of law. And this one tells of a gap that has been widening for two years, of a credit agreement that had to give ground twice, and of a cash balance where more than nine tenths belongs to somebody else.

What this analysis covers

• What Insperity actually does — the employer nobody puts on a business card
• How this stock landed on our desk
• The numbers across the years — what genuinely impresses
• What the filings say — five uncomfortable truths
• Valuation — what the market pays for this business
• Opportunities and risks at a glance
• A human bottom line
• Frequently asked questions
• Sources

What Insperity actually does — the employer nobody puts on a business card

Picture a company with forty employees. It needs payroll, payroll taxes, health coverage, workers compensation, employment contracts, someone who knows termination law and someone who knows which form looks different in California than in Texas. It is far too small to justify an HR department. That is where Insperity steps in: the company from Kingwood, Texas, becomes the legal co-employer of the workforce — in industry terms a professional employer organization, or PEO. The people keep working at the client site but sit on Insperity's payroll. The filings call them worksite employees.

The economics rest on scale: because Insperity bundles the workforces of many small firms into one large group, it obtains health insurance terms a forty-person shop could never negotiate alone. In 2025 it paid an average of 310,089 worksite employees per month, up 1 percent. Insperity itself employed about 4,200 people as of December 31, 2025.

The offering comes in four versions. HR 360 is the full package and the largest source of revenue. HR 360 Select Edition is the leaner variant for larger mid-market clients. HR Core is payroll and human capital management without co-employment. And HR Scale is the new one: a joint solution built with Workday, Inc. on top of Workday's human capital management software, priced above HR 360 and aimed at companies with roughly 150 to 5,000 worksite employees. The annual report gives the start date: the first clients were expected to begin using HR Scale in the first quarter of 2026. Everything is reported in a single segment called HR Solutions — so there is no separate profit and loss statement for HR Scale.

And now the line that explains everything. Insperity bills the client gross: wages plus a markup expressed as a percentage of payroll cost. Only the markup counts as revenue. Out of that markup Insperity pays payroll taxes, health benefits and workers compensation; what is left is gross profit. That frames the central tension of this analysis, and it runs through every chapter below: the markup has to rise faster than health costs — but every price increase costs clients, and the same fixed costs spread worse across fewer heads. This is not theory. It is precisely what happened in 2025 and in the first quarter of 2026.

How this stock landed on our desk

We run roughly 3,500 stocks through our scanners every day. Insperity reached the research list through our in-house stock scanner "Turnaround Candidates": rank 19 of 62 U.S. hits, turnaround check 7 of 8, as of July 25, 2026. To reproduce it: open the scanner, set the country filter to U.S., sort by the turnaround check column. These lists are recalculated daily — the rank and the score are a dated snapshot, not a permanent state.

The model has two mandatory pillars. Break either one and a stock drops out instantly, no matter how the business is doing:

• Pillar 1 — the crash: the stock must trade at least 50 percent below its all-time high. No real crash, no turnaround. This is the pillar a stock loses exactly when things go well — the higher the price, the closer the exit.
• Pillar 2 — survival: the Altman Z score (an insolvency early-warning measure built from several balance sheet ratios) must be at least 1.1, stockholders equity must be positive, and no more than one balance sheet warning flag may be present. Plus tradability: price above $3 and average daily turnover above $2 million.

And this is where the hook carries an expiry date — a calculable one this time. The dividend-adjusted all-time high of Insperity stock dates from July 26, 2019, at roughly $116. Half of that is about $58. On July 24, 2026, the stock closed at $48.35 — roughly 58 percent below the all-time high, leaving only about 20 percent of room before the exclusion. For reference: on July 28, 2025, the same stock stood at $61.42. So if the price keeps climbing, Insperity leaves this list — not because the business got worse, but because it looks better. Pillar 2, by contrast, is comfortably met: our fundamental data put the Altman Z score at 4.05 (as of July 26, 2026), because $6.8 billion of revenue meets only $2.2 billion of total assets. Equity is positive — but only $67 million of it. More on that shortly.

Only after the mandatory pillars does the actual turnaround check come into play: eight points, four from the quarterly numbers (revenue direction, net margin, operating cash flow, balance sheet healing) and four from market behavior (price above the 50-day line, relative strength of the last three months against the last twelve, net insider buying, institutional accumulation). A stock is listed once it reaches at least 6 of 8; Insperity stood at 7 on July 25, 2026. We described the same mechanism earlier in this series for another service provider to U.S. small businesses that arrived through the same list — see our CBIZ analysis. Remember the principle: a scanner sorts by attributes, not by reasons. The reason has to be read.

The numbers across the years — what genuinely impresses

Start with what deserves credit: Insperity is not losing clients wholesale, and revenue has risen in every recent year. $4,973 million (2021), $5,939 million (2022), $6,486 million (2023), $6,581 million (2024) and $6,812 million (2025). That is 37 percent growth in four years in a business whose contracts can generally be cancelled on 30 days notice. Client retention has improved too: from 81 percent in 2024 to 83 percent in 2025, against a five-year average of 84 percent. The fiscal year matches the calendar year.

Now the line underneath. Gross profit — what is left after payroll taxes, health benefits and workers compensation — did not follow revenue. In 2025 it left it behind:

The gross profit series: $820 million (2021), $1,011 million (2022), $1,037 million (2023), $1,052 million (2024) — and then $900 million (2025). Operating expenses over the same years: $646, $761, $818, $935, $910 million. In 2024 there were still $117 million between the two lines; in 2025 they crossed. Operating income fell accordingly from $250 million (2022) through $219 million (2023) and $117 million (2024) to minus $10 million. The bottom line for 2025 was a net loss of $7 million and diluted loss per share of $0.19 — after $4.64 of earnings per share in 2022.

What deserves noting is how disciplined the cost side was: operating expenses fell 3 percent in 2025, and per worksite employee per month from $253 to $245. The problem was not an overgrown head office. It sat one floor above.

What the filings say — five uncomfortable truths

Uncomfortable truth No. 1: pricing rose 3 percent, health costs 9 percent

The annual report explains the collapse in four sentences, without hedging:

"Gross profit decreased 14% to $900 million. The decrease was primarily due to a 15% decrease in gross profit per WSEE, which was partially offset by a 1% increase in the average number of WSEEs paid per month. Gross profit per WSEE paid per month reflected, in part, a 3% pricing increase offset by a 6% increase in direct costs per WSEE. The increase in direct costs per WSEE was primarily attributable to a 9% increase in benefits costs per participant."

— Insperity, Inc., Form 10-K for 2025, Management's Discussion and Analysis

Three percent of pricing against nine percent of cost is not a soft patch in the cycle. It is a pricing error with a lead time. Insperity fixes its rates a year in advance and has to estimate what its clients' workforces will run up in medical bills over the coming year. When the estimate is wrong, Insperity carries the difference — not the client. That is the core of the business and its single largest risk.

Uncomfortable truth No. 2: the gap is closing — and the price is paid in clients

The first quarter of 2026 looks better. Benefits cost per covered employee rose only 5.2 percent, against an unchanged pricing increase of 3 percent. Six percentage points of gap became 2.2:

What that progress costs is in the filing too, stated plainly enough that you read it twice:

"During Q1 2026, average WSEEs paid decreased 1% compared to Q1 2025. The number of WSEEs paid from new client sales and client retention decreased due in part to our margin recovery efforts, while the net change in our client base increased compared with Q1 2025."

— Insperity, Inc., Form 10-Q for the quarter ended March 31, 2026

In plain terms: Insperity is deliberately accepting client losses to rescue the margin. That is sound management and uncomfortable ownership, because the first quarter still came in weaker than the year before — $62 million of operating income against $68 million, $33 million of net income against $51 million, $0.88 per diluted share against $1.35. Two things belong in the calculation for fairness. The first quarter of 2026 carried $9 million of restructuring charges from the workforce realignment announced in February 2026; without that item operating income would have exceeded the prior-year figure. And the effective tax rate jumped from 29 percent to 48 percent because equity awards vested at a price below their grant price — that alone cost $10 million of additional tax. A fallen share price literally raises the tax bill here.

One framing point matters: the first quarter is Insperity's seasonally strongest, because U.S. payroll tax bases reset at the start of the year. Multiplying $62 million by four is guaranteed to be wrong — 2025 opened with a $68 million first quarter and ended at minus $10 million for the year.

Uncomfortable truth No. 3: $555 million in cash — $519 million of it belongs to others

Here the treasurer trap from the opening snaps shut at full force. The quarterly report reports a cash position that sounds like a fortress, and dissolves it in the same sentence:

Of $555 million in cash, cash equivalents and marketable securities at March 31, 2026, roughly $415 million was payable in April 2026 — withheld federal and state income taxes, employment taxes and other payroll deductions, that is, other people's money on its way to the tax authorities. Another $104 million represented client prepayments. That leaves about $36 million. Working capital stood at $142 million (December 31, 2025: $102 million; December 31, 2024: $155 million). The year-end 2025 picture was the same: $660 million of cash, of which $468 million was payable in early January and $135 million was client prepayments.

The same pattern governs cash flow: operating cash flow swung from plus $198 million (2023) to plus $520 million (2024) and then to minus $278 million (2025). Those swings do not measure earning power; they measure which day of the week a payroll date happened to fall on relative to the balance sheet date. At a payroll processor, treating operating cash flow as a quality metric means measuring the calendar.

Uncomfortable truth No. 4: the lenders gave ground twice in 2025

Insperity has $369 million drawn on its revolving facility and $67 million of stockholders equity on the balance sheet (March 31, 2026). The ratio is unusual — and it left marks in the credit agreement during 2025:

The Form 8-K filed December 16, 2025, carries the detail of the second step: the revolving commitment rose from $650 million to $750 million, the accordion option from $700 million to $800 million, maturity was extended to December 15, 2028 — and the permitted leverage ratio rose from 3.00 to 3.75. The definition of EBITDA was amended as well. A ceiling does not get raised because there is plenty of room under it. At March 31, 2026, $369 million was drawn plus a $1 million letter of credit, leaving $380 million unused. The report confirms compliance with all financial covenants at that date.

Over the same period Insperity kept paying $23 million of dividends per quarter — $90 million in 2025, against a full-year loss of $7 million. Add $19 million of share repurchases and $31 million of capital expenditure. That dividends were carved out of the interest coverage covenant is therefore not a technicality: it is the condition under which that payout can continue as it is.

Uncomfortable truth No. 5: one carrier, one sales force — both stretched

Two concentrations that sit far apart in the filings and belong side by side. First: roughly 85 percent of health insurance costs run through the policy with UnitedHealthcare. One carrier therefore governs the company's largest cost block. To its credit, Insperity renegotiated: an amendment dated November 3, 2025, extends the arrangement through 2028, holds out additional cost savings starting in 2026, and gives Insperity the right to elect annually whether it stands behind each participant's claims up to $500,000, $750,000 or $1 million. For 2026 the company chose the most cautious step: $500,000. That is precisely the lever that likely braked the cost curve in the first quarter of 2026 — and it costs premium.

Second: the sales force has shrunk sharply. The average number of business performance advisors fell from 769 in 2024 to 612 in 2025, a decline of more than a fifth. Trained advisors went from 698 to 599. That matters because Insperity loses roughly 17 percent of its base to attrition every year; at 310,089 worksite employees that is more than 50,000 heads to replace just to stand still. In the first quarter of 2026 headcount in sales, service and support fell another 8 percent, while advertising spend rose 57 percent to $11 million. At the same time HR Scale is launching — a new, higher-priced offering aimed at exactly the larger clients — and it did show up in the mid-market in the first quarter of 2026: worksite employees there rose 9 percent, lifting the mid-market share of the total from 26 percent to 29 percent.

How powerfully a single cost block can turn a service business is something this series has already shown at a manager of workers compensation costs — see our CorVel analysis.

Valuation — what the market pays for this business

As a dated anchor: on July 24, 2026, the stock closed at $48.35; with 38,169,182 shares outstanding (as of April 23, 2026) that is a market capitalization of roughly $1.85 billion. Against 2025 revenue of $6,812 million that is a price-to-sales ratio of about 0.27 — which says little about a business that converts only 13 percent of revenue into gross profit. No price-to-earnings ratio can be formed for 2025 because there were no earnings. On the adjusted figures — $39 million of adjusted net income and $1.03 of adjusted earnings per share — the multiple would be roughly 47 times.

The more telling view is on what once was and might be again: between 2021 and 2023 Insperity earned between $124 million and $179 million of net income. On that level today's market capitalization corresponds to a multiple between 10 and 15. Book value is no anchor here: $1.755 per share gives a price-to-book ratio of about 27.5 — a legacy of years of buybacks, not of losses. Retained earnings still stood at $648 million on March 31, 2026.

The professionals are split. The average price target in our fundamental data is $43.75 (as of July 26, 2026), below the July 24 close. At the same time those estimates call for $2.05 of earnings per share this year and $2.80 next year — after minus $0.19 in 2025. Anyone who trusts that estimate is paying roughly 17 times the earnings of the year after next. Anyone who does not is paying for a company with an operating loss. Both describe the same stock. Also notable is short interest of about 12.4 percent of the float: a meaningful part of the market is still betting against it.

Opportunities and risks at a glance

What speaks for it:

• The cost curve is measurably bending: benefits cost per covered employee rose only 5.2 percent in the first quarter of 2026 after 9 percent in 2025, against an unchanged pricing increase of 3 percent.
• The largest cost block was renegotiated: the amendment of November 3, 2025, extends the UnitedHealthcare arrangement through 2028, holds out savings from 2026 and allows the per-participant exposure to be capped at $500,000, the level elected for 2026.
• Client retention improved: 83 percent in 2025 after 81 percent in 2024.
• Cost discipline is working: operating expenses fell 3 percent to $910 million in 2025, and per worksite employee per month from $253 to $245; in February 2026 a further 4 percent of non-sales positions were eliminated.
• The chief executive bought roughly $12.6 million of stock between March 17 and June 3, 2026 — reported on Form 4, transaction code P.
• The mid-market business is growing: worksite employees up 9 percent in the first quarter of 2026, share of the total from 26 percent to 29 percent.

What speaks against it:

• The turnaround is unproven: first-quarter 2026 operating income of $62 million came in below the prior year's $68 million, net income of $33 million below $51 million.
• The margin is being paid for in clients: worksite employees paid fell 1 percent in the first quarter of 2026, attributed in the filing in part to margin recovery efforts.
• The balance sheet is thin: $67 million of stockholders equity within total assets of $2,196 million (March 31, 2026), roughly 3 percent.
• Credit covenants were loosened twice in 2025 — dividends carved out of interest coverage, the leverage ceiling raised from 3.00 to 3.75.
• The $90 million of dividends paid in 2025 was not covered by earnings and was effectively funded through the revolving facility.
• One carrier bears roughly 85 percent of health insurance costs; client contracts are generally cancellable on 30 days notice and attrition runs at roughly 17 percent a year.
• The sales force shrank by more than a fifth in 2025 while HR Scale is only starting and carries no separate segment reporting.

A human bottom line

Back to the treasurer from the opening. We started at $45.6 billion and landed at $900 million of gross profit and minus $10 million of operating income. Run the same arithmetic on the cash: $555 million sounds like a cushion, and $519 million of it belongs to the tax authorities and to clients. At Insperity nearly everything that looks large is merely passing through. What stays is a narrow spread — and that spread decides everything.

What we like about this case: the company does not talk around it. It writes into its own filing that it is losing clients because it is raising prices. It quantifies the cost increase to the decimal. It reports the loosening of its credit covenants in a sentence you cannot miss if you look for it. And its chief executive put his own money into the stock twice in the spring of 2026, while the price sat on the floor.

What we do not like: the proof is still missing. A single, seasonally strong quarter with operating income below the prior year is a direction, not a turn. The question everything hangs on is easy to ask and will be answered within a year: do health costs per covered employee rise durably slower than prices — and are enough clients left for the progress to show up in dollars rather than only in percentage points? We will not tell you what to do with that. We only tell you where to look. What you make of it is your decision. And that is exactly how it should be.

Sources

• Form 10-Q for the quarter ended March 31, 2026, filed May 1, 2026 — Insperity, Inc., CIK 0001000753 (most recent periodic report)
• Form 10-K for 2025, filed February 11, 2026 — source of the 2025, 2024 and 2023 annual figures, client retention, sales force data and the UnitedHealthcare disclosures
• Form 10-K for 2024, filed February 11, 2025; the 2021 and 2022 annual figures come from the XBRL data of the 2022 and 2023 annual reports
• Form 8-K dated February 10, 2026, Items 2.02 and 2.05 — realignment plan: roughly 4 percent of non-sales positions, about $9 million of one-time charges
• Form 8-K dated December 16, 2025, Items 1.01 and 2.03 — Eighth Amendment to the credit agreement: $750 million commitment, maturity December 15, 2028, leverage ceiling from 3.00 to 3.75
• Form 8-K dated November 3, 2025, Items 1.01 and 2.02 — UnitedHealthcare amendment: extension through 2028, annual election of $500,000 / $750,000 / $1 million per participant
• Forms 4 dated March 19, 2026, and June 4, 2026 — chief executive purchases of 201,987 and 233,000 shares
• Fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q): metrics, price and valuation data, as of July 24 to 26, 2026
• Hook: our in-house stock scanner "Turnaround Candidates" — rank 19 of 62 U.S. hits, turnaround check 7 of 8, as of July 25, 2026; the lists are recalculated daily.

This analysis is journalistic commentary based on publicly available documents. It is not investment advice, not a recommendation to buy or sell, and not a solicitation to buy or sell securities. Stocks can lose value at any time, up to and including total loss. All figures carry their respective reference dates and may have changed since publication. The author holds no position in Insperity, Inc. at the time of publication.